Literature DB >> 1790309

Factors influencing the protein binding of vancomycin.

W G Shin1, M G Lee, M H Lee, N D Kim.   

Abstract

Various factors influencing the protein binding of vancomycin were examined using equilibrium dialysis method. Four per cent human serum albumin (HSA) and/or 0.08 per cent alpha-1-acid glycoprotein (AAG), dissolved in isotonic phosphate buffer, were dialyzed against isotonic phosphate buffer of pH 7.4 using Spectrapor 2 membrane. The protein binding of vancomycin to 0.08 per cent AAG was dependent on vancomycin concentrations; the values ranged from 21.1 per cent at the vancomycin concentration of 20 micrograms ml-1 to 5.30 per cent at 2400 micrograms ml-1. However, binding to 4 per cent HSA was relatively constant, 8.79 +/- 2.43 per cent over a vancomycin concentration range of 20-2400 micrograms ml-1. The values to 4 per cent HSA alone and 0.08 per cent AAG alone did not predict the greater binding of vancomycin in the presence of both proteins, especially at higher concentrations of vancomycin; the values to 4 per cent HSA with 0.08 per cent AAG were constant, 26.3 +/- 3.74 per cent, at the vancomycin concentration range of 20-2400 micrograms ml-1. This suggested an interaction between the proteins, which resulted in enhanced binding of vancomycin. The protein binding of vancomycin to 4 per cent HSA with 0.08 per cent AAG was not influenced by the different incubation temperatures (4 degrees, 22 degrees, and 37 degrees), quantities of heparin (up to 40 units ml-1) or AAG (up to 0.16 per cent), or buffers (isotonic phosphate buffer of pH 7.4, phosphate buffer of pH 7.4 and 0.9 per cent NaCl solution) at the vancomycin concentration of 80 micrograms ml-1. Vancomycin was found to be stable in human serum albumin or in isotonic phosphate buffer of pH 7.4.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1790309     DOI: 10.1002/bdd.2510120902

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  3 in total

1.  Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition.

Authors:  S H Kim; Y M Choi; M G Lee
Journal:  J Pharmacokinet Biopharm       Date:  1993-02

2.  Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats.

Authors:  Eun Hye Gwak; Hee Young Yoo; So Hee Kim
Journal:  Biomol Ther (Seoul)       Date:  2020-07-01       Impact factor: 4.634

Review 3.  Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Kazuaki Matsumoto; Kazutaka Oda; Kensuke Shoji; Yuki Hanai; Yoshiko Takahashi; Satoshi Fujii; Yukihiro Hamada; Toshimi Kimura; Toshihiko Mayumi; Takashi Ueda; Kazuhiko Nakajima; Yoshio Takesue
Journal:  Pharmaceutics       Date:  2022-02-23       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.